CO6700844A2 - New crystalline forms of (e) -3- (2- (1 - ((2- (5-bromo-pyrimidin-2-yl) -3- cyclopentyl-1 methyl-1h indole-6-carbonyl) -amino) -cyclobutyl-3-methyl-3h-bacimidazol-5 -) - acrylics as vhc inhibitors - Google Patents

New crystalline forms of (e) -3- (2- (1 - ((2- (5-bromo-pyrimidin-2-yl) -3- cyclopentyl-1 methyl-1h indole-6-carbonyl) -amino) -cyclobutyl-3-methyl-3h-bacimidazol-5 -) - acrylics as vhc inhibitors

Info

Publication number
CO6700844A2
CO6700844A2 CO13057890A CO13057890A CO6700844A2 CO 6700844 A2 CO6700844 A2 CO 6700844A2 CO 13057890 A CO13057890 A CO 13057890A CO 13057890 A CO13057890 A CO 13057890A CO 6700844 A2 CO6700844 A2 CO 6700844A2
Authority
CO
Colombia
Prior art keywords
methyl
pyrimidin
indole
cyclobutyl
cyclopentyl
Prior art date
Application number
CO13057890A
Other languages
Spanish (es)
Inventor
Rolf Stefan Brickl
Shirlynn Chen
Jinchin Chung
Mayur Suryakant Dudhedia
Danping Li
Zhi Lu
Siddharthya Mujumdar
Chitra Telang
Richard Varsolona
Zeren Wang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6700844(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6700844A2 publication Critical patent/CO6700844A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención reclama sales sódicas del compuesto denominado ácido (E)-3-[2- (1- {[2-(5-bromo-pirimidin-2-il)-3-ciclopentil- 1 -metil- 1H-indol-6-carbonil]-amino} - ciclobutil)-3-metil-3H-bencimidazol-5-il]-acrílico, de fórmula (I):Así como composiciones farmacéuticas que las contienen, las cuales son útiles en el tratamiento de infecciones mediadas por el Virus de la Hepatitis C (VHC).The present invention claims sodium salts of the compound called (E) -3- [2- (1- {[2- (5-bromo-pyrimidin-2-yl) -3-cyclopentyl-1-methyl-1H-indole- 6-carbonyl] -amino} -cyclobutyl) -3-methyl-3H-benzimidazol-5-yl] -acrylic, of formula (I): As well as pharmaceutical compositions containing them, which are useful in the treatment of mediated infections for the Hepatitis C Virus (HCV).

CO13057890A 2010-09-30 2013-03-22 New crystalline forms of (e) -3- (2- (1 - ((2- (5-bromo-pyrimidin-2-yl) -3- cyclopentyl-1 methyl-1h indole-6-carbonyl) -amino) -cyclobutyl-3-methyl-3h-bacimidazol-5 -) - acrylics as vhc inhibitors CO6700844A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38824210P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
CO6700844A2 true CO6700844A2 (en) 2013-06-28

Family

ID=44759789

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13057890A CO6700844A2 (en) 2010-09-30 2013-03-22 New crystalline forms of (e) -3- (2- (1 - ((2- (5-bromo-pyrimidin-2-yl) -3- cyclopentyl-1 methyl-1h indole-6-carbonyl) -amino) -cyclobutyl-3-methyl-3h-bacimidazol-5 -) - acrylics as vhc inhibitors

Country Status (21)

Country Link
US (2) US8598183B2 (en)
EP (1) EP2621921A1 (en)
JP (1) JP2013543495A (en)
KR (1) KR20130108326A (en)
CN (1) CN103153987A (en)
AP (1) AP2013006733A0 (en)
AR (1) AR083256A1 (en)
AU (1) AU2011307346A1 (en)
BR (1) BR112013007700A2 (en)
CA (1) CA2813179A1 (en)
CL (1) CL2013000578A1 (en)
CO (1) CO6700844A2 (en)
EA (1) EA201300422A1 (en)
EC (1) ECSP13012552A (en)
MA (1) MA34548B1 (en)
MX (1) MX2013003551A (en)
PE (1) PE20131351A1 (en)
SG (1) SG188376A1 (en)
TW (1) TW201307327A (en)
UY (1) UY33632A (en)
WO (1) WO2012044520A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013007700A2 (en) * 2010-09-30 2019-09-24 Boehringer Ingelheim Int solid state forms of a potent hcv inhibitor
AR089078A1 (en) * 2011-12-06 2014-07-30 Sanofi Sa CRYSTAL FORMS OF [(S) -1-CARBAMOIL-2- (PHENYL-PYRIMIDIN-2-IL-AMINO) -ETIL] -AMIDE OF ACID 2- (2-METHYLAMINE-PYRIMIDIN-4-IL) -1H-INDOL- 5-CARBOXILICO
US20130261134A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Mesylate salt forms of a potent hcv inhibitor
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426408T2 (en) 1993-09-28 2001-07-12 Scherer Gmbh R P Manufacture of soft gelatin capsules
US5821242A (en) * 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
ES2431314T3 (en) 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Viral Polymerase Inhibitors
AU2006213769B2 (en) 2005-02-11 2012-10-04 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles
JP5284101B2 (en) 2005-11-09 2013-09-11 ノバルティス アーゲー Method for producing pharmaceutical composition using temporary plasticizer
BR112013007700A2 (en) * 2010-09-30 2019-09-24 Boehringer Ingelheim Int solid state forms of a potent hcv inhibitor

Also Published As

Publication number Publication date
EA201300422A1 (en) 2013-09-30
CA2813179A1 (en) 2012-04-05
PE20131351A1 (en) 2013-12-04
WO2012044520A1 (en) 2012-04-05
CL2013000578A1 (en) 2013-08-02
EP2621921A1 (en) 2013-08-07
AR083256A1 (en) 2013-02-13
SG188376A1 (en) 2013-04-30
UY33632A (en) 2012-04-30
CN103153987A (en) 2013-06-12
JP2013543495A (en) 2013-12-05
ECSP13012552A (en) 2013-06-28
TW201307327A (en) 2013-02-16
KR20130108326A (en) 2013-10-02
US8598183B2 (en) 2013-12-03
US20140057928A1 (en) 2014-02-27
AU2011307346A1 (en) 2013-02-21
US20120122887A1 (en) 2012-05-17
MA34548B1 (en) 2013-09-02
AP2013006733A0 (en) 2013-02-28
MX2013003551A (en) 2013-05-01
BR112013007700A2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
CY1123661T1 (en) CRYSTAL FORM OF AN MDM2 INHIBITOR
CO6561783A2 (en) FLAVIVIRIDAE VIRUS INHIBITORS
CY1118450T1 (en) DIAHYDROPYRIDONE P1 AS AN OPTIONS OF CHIA
CY1118478T1 (en) AZAZIDAZOL OR DIAZANDAZOLI TYPE PRODUCTS FOR TREATMENT OF PAIN
CO7131360A2 (en) Novel substituted cyclic n-pyridinyl amides as kinase inhibitors
UY32174A (en) NEW SUBSTITUTED HETEROCICLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
PE20160200A1 (en) BROMODOMINES INHIBITORS
CY1118093T1 (en) PHARMACEUTICAL FORMS CONTAINING DERIVATIVES 1- (BHTA-D-GLYCOPYRANOZYL) -2-THYNYLMETHYLBENZOLI AS SGLT ANALYPES
EA201490724A1 (en) SUBSTITUTED COMPOUNDS OF TETRAHYDROISOCHINOLINE AS INHIBITORS OF XIA
ECSP12011684A (en) FLAVIVIRIDAE VIRUS INHIBITORS.
UA110241C2 (en) Herbicides and fungicides active phneylisoxazoline 3-5-carboxamide and 3- phneylisoxazoline -5-thioamides
CO2018000589A2 (en) Oxiesterols and pharmaceutical compositions containing them
DOP2014000152A (en) BROMODOMINIUM INHIBITORS
EA201500557A1 (en) ANTI-HELMINET COMPOUNDS, COMPOSITIONS AND METHODS OF THEIR USE
ECSP12012104A (en) VIRUS FLAVIVIRIDAE INHIBITORS
CU20090017A7 (en) PEPTIDOMIMETICS OF SMAC USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (IAP)
CR20110684A (en) IMIDAZOLIDIN-2-ONA 1,3-DISPOSED DERIVATIVES AS CYP17 INHIBITORS
UA111626C2 (en) DIGIDROCHINOLIN-2-ON DERIVATIVES
NI200900151A (en) NEW PROCEDURE FOR THE SYNTHESIS OF AGOMELATIN.
IN2014CN01024A (en)
CY1118399T1 (en) Benzofuran compounds for viral infections c treatment
EA201690888A1 (en) NEW HETEROCYCLIC COMPOUNDS
GT201400167A (en) NEW DERIVATIVES OF BENCIL SULFONAMIDE USEFUL AS INHIBITORS OF MOGAT-2
EA201490435A1 (en) ANTIBACTERIAL 3,4-DIHYDRO-1N- [1,8] NAFTYRIDINOES FIXED BY PIPERIDINYL
UY34722A (en) SALTS OF 5 - [(1R) -2 - ({2- [4- (2,2-DIFLUORO-2-PHENYLETOXY) PHENYL] ETHYL} AMINO) -1-HYDROXYETHYL] -8- HYDROXYQUINOLIN-2 (1H) - ONA